NO20005041L - FremgangsmÕte for Õ inhibere MRP1 - Google Patents

FremgangsmÕte for Õ inhibere MRP1

Info

Publication number
NO20005041L
NO20005041L NO20005041A NO20005041A NO20005041L NO 20005041 L NO20005041 L NO 20005041L NO 20005041 A NO20005041 A NO 20005041A NO 20005041 A NO20005041 A NO 20005041A NO 20005041 L NO20005041 L NO 20005041L
Authority
NO
Norway
Prior art keywords
procedure
mrp1
inhibiting mrp1
inhibiting
mediated
Prior art date
Application number
NO20005041A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005041D0 (no
Inventor
Joseph Michael Gruber
Sean Patrick Hollinshead
Bryan Hurst Norman
Joseph Wendell Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20005041D0 publication Critical patent/NO20005041D0/no
Publication of NO20005041L publication Critical patent/NO20005041L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20005041A 1998-04-08 2000-10-06 FremgangsmÕte for Õ inhibere MRP1 NO20005041L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8108898P 1998-04-08 1998-04-08
PCT/US1999/007615 WO1999051236A1 (en) 1998-04-08 1999-04-07 Methods for inhibiting mrp1

Publications (2)

Publication Number Publication Date
NO20005041D0 NO20005041D0 (no) 2000-10-06
NO20005041L true NO20005041L (no) 2000-10-06

Family

ID=22162031

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005041A NO20005041L (no) 1998-04-08 2000-10-06 FremgangsmÕte for Õ inhibere MRP1

Country Status (17)

Country Link
US (1) US6221876B1 (id)
EP (1) EP1067932A4 (id)
JP (1) JP2002510632A (id)
KR (1) KR20010042481A (id)
CN (1) CN1296410A (id)
AU (1) AU3550299A (id)
BR (1) BR9909446A (id)
CA (1) CA2327452A1 (id)
EA (1) EA200001035A1 (id)
HU (1) HUP0102548A2 (id)
ID (1) ID26804A (id)
IL (1) IL138393A0 (id)
NO (1) NO20005041L (id)
PL (1) PL343320A1 (id)
SK (1) SK14992000A3 (id)
TR (1) TR200002804T2 (id)
WO (1) WO1999051236A1 (id)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2255294T3 (es) * 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
DE60016039T2 (de) * 1999-12-22 2005-08-11 Eli Lilly And Co., Indianapolis Verfahren und verbindungen für die hemmung von mrp1
WO2001096346A1 (en) * 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
US7064131B2 (en) 2001-04-09 2006-06-20 Eli Lilly And Company Compounds and methods for inhibiting MRP1
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
WO2005113004A2 (en) * 2004-05-14 2005-12-01 The Cleveland Clinic Founfation Small molecule inhibitors for mrp1 and other multidrug transporters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands

Also Published As

Publication number Publication date
NO20005041D0 (no) 2000-10-06
KR20010042481A (ko) 2001-05-25
CA2327452A1 (en) 1999-10-14
JP2002510632A (ja) 2002-04-09
EP1067932A4 (en) 2001-11-14
BR9909446A (pt) 2000-12-12
TR200002804T2 (tr) 2001-02-21
SK14992000A3 (sk) 2001-06-11
AU3550299A (en) 1999-10-25
US6221876B1 (en) 2001-04-24
IL138393A0 (en) 2001-10-31
CN1296410A (zh) 2001-05-23
HUP0102548A2 (hu) 2001-11-28
ID26804A (id) 2001-02-08
PL343320A1 (en) 2001-08-13
WO1999051236A1 (en) 1999-10-14
EA200001035A1 (ru) 2001-04-23
EP1067932A1 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
ATE316531T1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
ATE231149T1 (de) (1,8)-naphthyridinderivate derivate mit antiviraler wirkung
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
PE20011085A1 (es) Compuestos isoxazolquinolin o imidazolquinolin como inhibidores de la proteina resistente a multifarmacos
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
DE69918465D1 (de) Sulfonamidhydroxamate
NO20005041L (no) FremgangsmÕte for Õ inhibere MRP1
NO20005042L (no) FremgangsmÕter for Õ inhibere MRP1
NO20002589D0 (no) Bifenylamidinderivater
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
ATE323492T1 (de) Piperazin- und homopiperazinderivate zur hemmung der zellenadhäsion und zelleninfiltration
BR0212899A (pt) Compostos orgânicos
TR200002851T2 (tr) MRP1'i inhibe etmek için yöntemler.
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
DE60222459D1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamide als factor xa inhibitoren
DK1163258T3 (da) Derivater af 22R-hydroxycholesta-8, 14-dien til inhiberingen af meiosis
DK0963998T3 (da) Azasteroidforbindelse til behandling eller prævention af prostatacancer
HK1035712A1 (en) Benflumetol derivatives and their use against parasitical protozoa and trematodes.
DK1192191T3 (da) Fremgangsmåde til fremstilling af kondensationsforbindelser
ECSP982576A (es) Derivados de epotilona
ATE189813T1 (de) Prostaglandin-i-analoga
DE60205103D1 (de) Verbindungen und methoden zur hemmung von mrp1
DE60207709D1 (de) Verbindungen und methoden zur inhibierung von mrp1
YU15395A (sh) Antitrombonski agensi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application